ESMO25: On partnerships between pharma and diagnostic developers, with Jane Li

At ESMO 2025 in Berlin, pharmaphorum sat down with Jane Li, Senior Director of Pharma CDx and CRO Partnership, Clinical Next Generation Sequencing Business, at Thermo Fisher Scientific to discuss the recent FDA approval for its oncomine Dx Target Test as a companion diagnostic (or CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim.

Li also explains how progress in precision oncology depends on close collaboration between pharma and diagnostic developers, and how through co-developing companion diagnostics CDx with targeted therapies, and aligning early with regulators, these partnerships ensure accurate patient-drug matching, faster approvals, and greater global access to breakthrough treatments.

Watch this and other conversations from ESMO 2025 here.